SIBN
$18.93
$-0.02 (-0.11%)-0.11%
After HoursLoading chart...
IndexN/A
Market Cap0.84B
Enterprise Value0.82B
Income$-0.01B
Sales$0.05B
EmployeesN/A
P/E-55.68
P/S4.27
P/B4.83
P/C-94.40
EV/EBITDA-74.90
EV/SalesN/A
EPS (ttm)-0.34
EarningsN/A
Gross Margin79.57%
Oper. Margin-11.11%
Profit Margin-9.41%
Volume0.20M
Shs Outstand0.04B
Change-0.11%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $167.18M | $138.89M | $106.41M | $90.15M | $73.39M | $67.30M | $55.38M | $47.98M |
| Cost of Revenue | $35.06M | $29.47M | $15.71M | $10.43M | $8.90M | $6.79M | $4.83M | $5.11M |
| Gross Profit | $132.12M | $109.42M | $90.70M | $79.72M | $64.48M | $60.51M | $50.55M | $42.87M |
| Gross Margin | 79.03% | 78.78% | 85.24% | 88.43% | 87.87% | 89.91% | 91.27% | 89.35% |
| Operating Expenses | $167.37M | $156.35M | $150.31M | $131.39M | $103.05M | $96.51M | $62.51M | $60.22M |
| Operating Income | $-35.25M | $-46.93M | $-59.61M | $-51.67M | $-38.57M | $-36.00M | $-11.96M | $-17.35M |
| Operating Margin | -21.08% | -33.79% | -56.02% | -57.31% | -52.55% | -53.50% | -21.61% | -36.16% |
| Net Income | $-30.91M | $-43.34M | $-61.26M | $-56.57M | $-43.70M | $-38.40M | $-17.45M | $-23.04M |
| Net Margin | -18.49% | -31.20% | -57.57% | -62.75% | -59.54% | -57.06% | -31.51% | -48.01% |
| EPS (Basic) | $-0.75 | $-1.13 | $-1.79 | $-1.71 | $-1.50 | $-1.72 | $-1.10 | $-1.66 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $230.44M | $230.43M | $157.55M | $190.51M | $223.14M | $117.01M | $138.52M | $35.83M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $63.47M | $61.05M | $59.25M | $56.09M | $53.78M | $54.00M | $48.33M | $165.21M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $166.96M | $169.38M | $98.30M | $134.42M | $169.36M | $63.01M | $90.19M | $-129.38M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $166.96M | $169.38M | $98.30M | $134.42M | $169.36M | $63.01M | $90.19M | $-129.38M |
| Total Liabilities & Stockholders Equity | $230.44M | $230.43M | $157.55M | $190.51M | $223.14M | $117.01M | $138.52M | $35.83M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-30.91M | $-43.34M | $-61.26M | $-56.57M | $-43.70M | $-38.40M | $-17.45M | $-23.04M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-12.43M | $-18.71M | $-41.66M | $-39.53M | $-30.66M | $-31.63M | $-14.52M | $-17.53M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Why Si-Bone Stock Soared by Almost 20% on TuesdayThe Motley Fool Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026GlobeNewswire Inc. Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026GlobeNewswire Inc. SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025GlobeNewswire Inc. Why SI-Bone Stock Was Crushing It TodayThe Motley Fool DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of SI-Bone, Inc. Customers Whose Data May Have Been CompromisedGlobeNewswire Inc. 4 Recent Earnings Winners Riding Fresh Momentum in MayInvesting.com Here's Why You Should Add Inogen Stock to Your Portfolio NowBenzinga
Show 12 more stories
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?Benzinga SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024GlobeNewswire Inc. A Closer Look at 6 Analyst Recommendations For SI-BONEBenzinga Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research SI-BONE, Inc. Reports Financial Results for the First Quarter 2024GlobeNewswire Inc. Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?Zacks Investment Research What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?Zacks Investment Research What's in Store for Cardinal Health (CAH) in Q3 Earnings?Zacks Investment Research Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024GlobeNewswire Inc. Factors Setting the Tone For Lantheus' (LNTH) Q1 EarningsZacks Investment Research Cencora (COR) to Report Q2 Earnings: What's in the Cards?Zacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Discover more
You may be interested in